When the Supreme Court upheld the Food and Drug Administration’s approval of the abortion pill mifepristone in April, Cindy Adam “breathed a sigh of relief.”
Adam is the co-founder and CEO of Choix, a healthcare startup that offers telemedicine abortion and other reproductive health services in six states. The startup, which had been in the middle of closing its seed extension round, paused fundraising to await the Supreme Court’s decision, PitchBook reports.
The case is back to federal appeals court, and the question of whether Choix and others will be able to provide abortion care has been delayed.
But Choix and similar startups in the reproductive healthcare space face yet another battle: fundraising in 2023’s tough dealmaking environment, just as the legal landscape for abortion care shifts under their feet.
